2 Acute Kidney Injury in Patients with SARS-CoV-2.

- 4 Andrade Sierra Jorge^{1,2,3}, Delgado Astorga Claudia¹, Nava Vargas Miriam Gabriela¹, Rojas
- 5 Campos Enrique³, Arellano Arteaga Kevin Javier¹, Hernández Morales Karla¹, Andrade
- 6 Castellanos Carlos A¹, Andrade-Ortega Antonio de Jesús², González-Correa Luis Gerardo³.
- ¹Department of Internal Medicine. Hospital Civil de Guadalajara "Dr. Juan I Menchaca".
- 8 Guadalajara, Jalisco, Mexico.

3

13

14

22

23

24

25

26

- ²Department of Physiology, University Health Sciences Center, University of Guadalajara,
- 10 Guadalajara, Jalisco, Mexico.
- ³Medical Research Unit in Kidney Diseases, Specialties Hospital, National Western Medical
- 12 Center, Mexican Institute of Social Security. Guadalajara, Jalisco, Mexico.
- 15 **Corresponding author**: Jorge Andrade Sierra, MD, PhD
- 16 Department of Physiology, University Health Sciences Center (Centro Universitario de
- 17 Ciencias de la Salud), University of Guadalajara, Guadalajara, Jalisco, Mexico.
- 18 Sierra Mojada No. 950, Col. Independencia
- 19 Guadalajara, Jalisco, México CP 44340
- 20 Phone: +52 (33) 10585200
- 21 E-mail: jorg_andrade@hotmail.com

- 29 Coronavirus 2019 (COVID-19)
- 30 Systemic arterial hypertension (SAH)
- 31 Diabetes mellitus (DM)
- 32 Acute kidney injury (AKI)
- 33 C-reactive protein (CRP)
- 34 Procalcitonin (PCT)
- Lactate dehydrogenase (LDH)
- 36 Alanine aminotransferase (ALT)
- 37 SCr: Serum creatinine
- 38 Continuous Renal Replacement Therapy (CRRT)
- 39 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
- 40 Kidney Disease Improving Global Outcomes (KDIGO)
- 41 Acute Physiology and Chronic Health Evaluation II (APACHE II)
- 42 Sequential Organ Failure Assessment (SOFA)
- 43 Estimated glomerular filtration rate (eGFR)
- 44 Chronic Kidney Disease (CKD)
- Oxygen to fraction of inspired oxygen (PaO₂/FiO₂)
- 46 Body Mass Index (BMI)
- 47 Invasive mechanical ventilation (IMV)
- 48 Angiotensin-converting Enzyme Inhibitors (ACEi)
- 49 Angiotensin receptor blockers (ARBs)
- 50 Neutrophil gelatinase-associated lipocalin (NGAL)
- 51 Kidney injury molecule 1 (KIM-1)

52

53

Abstract

55

76

77

78

79

80

81

82

Background. Acute kidney injury (AKI) is associated with poor outcomes in patients infected 56 with SARS-CoV-2. Sepsis, direct injury to kidney cells by the virus, and severe systemic 57 inflammation are mechanisms implicated in its development. We investigated the association 58 between inflammatory markers (C-reactive protein, procalcitonin, D-dimer, lactate 59 60 dehydrogenase, and ferritin) in patients infected with SARS-CoV-2 and the development of AKI. Methods: A prospective cohort study performed at the Civil Hospital (Dr. Juan I. 61 Menchaca) Guadalajara, Mexico, included patients aged >18 years with a diagnosis of SARS-62 CoV-2 pneumonia confirmed by RT-PCR and who did or did not present with AKI (KDIGO) 63 64 while hospitalized. Biomarkers of inflammation were recorded, and kidney function was 65 estimated using the CKD-EPI formula. **Results:** 291 patients were included (68% men; mean age, 57 years). The incidence of AKI was 40.5% (118 patients); 21% developed stage 1 AKI, 66 67 6% developed stage 2 AKI, and 14% developed stage 3 AKI. The development of AKI was associated with phosphate higher (p = 0.002) (RR 1.39, CI 95% 1.13 - 1.72), high 68 69 procalcitonin levels at hospital admission (p = 0.005) (RR 2.09, CI 95% 1.26-3.50), and high APACHE scores (p = 0.011) (RR 2.0, CI 95% 1.17-3.40). The survival analysis free of AKI 70 71 according to procalcitonin levels and APACHE scores demonstrated a lower survival in patients with procalcitonin >0.5 ng/ml (p= 0.001) and APACHE >15 points (p = 0.004). 72 **Conclusions:** phosphate, high procalcitonin levels, and APACHE scores >15 were predictors 73 of AKI development in patients hospitalized with COVID-19. 74

75 **Key words.** Acute kidney injury, SARS-CoV-2, inflammatory markers.

Introduction.

83

The coronavirus 19 (COVID-19) pandemic, which originated with the novel coronavirus 84 (SARS-CoV-2), caused 318 thousand deaths in Mexico as of February 2022 (1). Older adults 85 with comorbidities(2, 3) are at a higher risk of complications from SARS-CoV-2 infections. 86 Kidney damage is one of the main complications and can be demonstrated by the presence of 87 hematuria, proteinuria (4-6), and the development of acute kidney injury (AKI), with high 88 incidence reported in hospitalized patients. (7-10) The severity leads to even higher mortality, 89 90 which has a multifactorial etiology (11, 12). Nevertheless, baseline characteristics, patient interventions in critical care, and organ crosstalk are mechanisms that influence the 91 appearance of AKI, but possible direct injury by the virus on kidney cells (podocytes, 92 proximal tubule cells, and the epithelial cells of Bowman's capsule (13-15)) and uncontrolled 93 systemic inflammation are factors that also influence its development and severity in patients 94 with COVID-19 (4, 16, 17). Inflammation and the consequent increase in some biomarkers 95 also appear to be associated with kidney damage and poor outcomes (2, 3, 18-25). In fact, the 96 therapeutic conduct for the prevention of developing AKI associated with COVID-19 is 97 98 similar to other etiologies (avoiding nephrotoxins, periodic review of serum creatinine (SCr), 99 urinary output, and hemodynamic monitoring), and in critically ill patients with COVID-19, it could reduce the appearance or severity of AKI (26). Our hospital has been a referral center 100 101 for patients without social security throughout the pandemic, and the limitations of some resources, such as urinary markers (neutrophil gelatinase-associated lipocalin (NGAL) and 102 103 kidney injury molecule 1 (KIM-1)), demand the use of low-cost inflammatory markers to predict the development of AKI. Our objective was to determine the existing association 104 between CRP, PCT, D-dimer, LDH, and ferritin levels and the development and severity of 105 AKI in patients hospitalized with pneumonia caused by SARS-CoV-2 without social security. 106

Methods

107

A prospective cohort study was performed in patients without social security coverage (Internal Medicine Department "Dr. Juan I. Menchaca" Civil Hospital in Guadalajara) from March 1, 2020, to March 1, 2021. All patients tested positive for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR). Based on the development of AKI using the Kidney Disease Improving Global Outcomes (KDIGO) classification, patients were classified into two groups: those with and without AKI. All patients in our study had normal

kidney function when admitted to the hospital, and we could not clinically determine 114 infections other than COVID-19. 115 116 Data collection 117 Quantitative polymerase chain reaction (RT-PCR) was used to determine the presence of SARS-CoV-2 in the nasopharyngeal swabs. All registered patients were tested for 118 inflammatory biomarkers (lactate dehydrogenase, ferritin, highly sensitive C-reactive protein, 119 120 D-dimer, and procalcitonin) upon admission and during hospitalization, and the following 121 data were collected: age, sex, history of smoking, alcoholism, prescribed medication use, and 122 comorbidities. The patients' anthropometric characteristics and presence of other infections (as documented by clinical evaluation or confirmed by any microbiological method) were also 123 124 recorded. The following biochemical variables were recorded: glucose, urea, SCr, uric acid, glycated hemoglobin, lipids, liver enzymes, electrolytes, hemoglobin, platelets, leukocytes, 125 126 and lymphocytes. Imaging studies, such as chest radiography or tomography, were performed on all patients upon hospital admission. Disease severity was assessed using the Acute 127 128 Physiology and Chronic Health Evaluation II (APACHE II) scoring system and sequential organ failure assessment (SOFA). Glomerular filtration rate (eGFR) was estimated using the 129 CKD-EPI formula (27). 130 131 Patients with chronic kidney disease (CKD), kidney transplant, obstructive kidney comorbidities, single kidney, neoplastic or autoimmune diseases, chronic use of anti-132 inflammatory drugs, and use of immunosuppressant drugs were excluded from the study. 133 134 The present study complies with the ethical principles for medical research in human beings as stipulated by the Declaration of Helsinki, 64th General Assembly, Fortaleza, Brazil, 135 136 October 2013, in addition to adhering to the standards of good clinical practice. All 137 procedures were performed according to the national regulations stipulated in the General Health Legal Guidelines for Health Care Research in Mexico, 2nd Title, Ethical Aspects for 138 Research in Human Beings, Chapter 1, Article 17. The study protocol was reviewed and 139 approved by the Ethics Committee of the Hospital Civil de Guadalajara, "Dr. Juan I 140 Menchaca" (HCG-JIM). Registration number: 17CI14 039 116 COFEPRIS. Guadalajara, 141 Jalisco, México. 142

Consent to participate statement

- All patients signed informed consent forms prior to hospital admission and provided consent
- to participate in the study.

Inflammatory markers

- **Procalcitonin.** Measurements were performed using the sandwich principle of an automated
- electrochemiluminescent immunoassay (Cobas E411,Roche).
- **Ferritin.** Measured using the immunoturbidimetric assay: Image 800 (Dyasys).
- 150 Highly sensitive C-reactive protein (hsCRP). Measurements were performed using a
- particle-enhanced immunoturbidimetric assay Cobas® c501 (Roche).
- **D-Dimer.** Measured using an immunochromatography assay: Ramp®.
- 154 Definitions

146

153

- SARS CoV-2 pneumonia: defined by the National Institutes of Health as individuals with
- SARS-CoV-2 infection confirmed by RT-PCR testing who have SpO₂ <94% on room air at
- sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
- 158 (PaO₂/FiO₂) <300 mmHg, respiratory frequency >30 breaths/min, or lung infiltrates >50%
- 159 (28).
- Acute kidney injury (AKI) (29): An abrupt decrease in GFR manifested by an increase in
- SCr or oliguria within the first 48 hours to seven days.
- We classified AKI considering only the increase in SCr:
- AKI1: Increase in SCr 1.5 to 1.9 times the baseline level, or an increase of >0.3 mg/dl.
- AKI2: Increase in SCr 2 to 2.9 times the baseline level.
- AKI3: Increase in SCr by 3 times the baseline, an increase of SCr >4 mg/dl, or the onset of
- 166 renal replacement therapy.
- 168 Statistical analysis
- The data are presented as mean \pm standard deviation or median, numbers, and percentages
- where appropriate. Student's t-test or the Mann-Whitney U test, depending on the distribution,
- was used to compare groups. The Cox proportional hazards model was used to estimate the
- 172 risk of AKI. Survival free of AKI and mortality was evaluated using the Kaplan-Meier test.
- 173 Statistical analysis was performed using SPSSTM software, version 17. Statistical significance
- 174 was set at p < 0.05.

175

Results

A total of 291 patients were eligible for inclusion in this study. The average age was 57±14 years, and 68% (n=198) corresponded to the male sex. At the time of hospital admission, the average body mass index (BMI) was 31 kg/m2, and approximately 40% of the patients had an associated comorbidity (DM or SAH). Ninety-five percent (95%) of the patients required some form of supplementary oxygen, and 20% were categorized as having severe illness requiring high-flow nasal cannulas and/or invasive mechanical ventilation (IMV) with an average of 9.5 days of hospitalization. On admission, no infectious processes other than the infection due to COVID-19, and all patients received dexamethasone at a dosage of 6 mg/day for 10 days during their hospital stay. The baseline characteristics of the patients are presented in TABLE 1.

Table 1. Demographic characteristics of patients with acute kidney injury (AKI) and COVID-19.

Characteristics	Total	AKI	No AKI	
Characteristics	n=291	n=118	n=173	
Age (years)	57 ± 14	61 ± 14*	54 ± 13*	
Sex- Masculine, n (%)	198 (68)	88 (75) *	110 (64) *	
Smoking, n (%)	89 (31)	41 (35)	48 (28)	
Hospitalization (days)	9.5 ± 7.0	12 ± 7.8*	7.7 ± 5.7*	
Comorbidities				
BMI, (Kg/m ²)	30.9 ± 6.9	31.2 ± 7.5	30.6 ± 6.4	
Diabetes, n (%)	113 (39)	55 (46.6) *	58 (33.5) *	
Hypertension, n (%)	112 (38)	58 (49.2) *	54 (31.2) *	
Oxygen requirement n (%)				
No use	5 (1.7%)		5 (2.9%)	
Nasal prongs	94 (32.3%)	30 (25.5%)	64 (37%)	
Mask	133 (45.7%)	49 (41.5%)	84 (48.6%)	
High flow	42 (14.4%)	28 (23.7%)	14 (8 %)	
CPAP	1 (0.3%)		1 (0.6)	
IMV	16 (5.5%)	11 (9.3%)	5 (2.9)	

Recovery from AKI, n (%)		
Yes	 	
	65 (55)	
No	 53 (45)	

AKI: acute kidney injury; **BMI:** body mass index; **CRP:** C-reactive protein; **LDH:** lactate dehydrogenase; **CPAP:** continuous positive airway pressure; **IMV:** invasive mechanical ventilation. **ACEi or ARBs:** angiotensin-converting enzyme inhibitors or angiotensin receptor blockers *p<0.05 Comparison between groups with and without AKI.

190

191

192

193

194

195

196

197 198

199

200

201

202

203204

205

206

207

208209

210

211

212

213

214

215

216

217

Acute kidney injury (AKI): AKI was recorded in 40.5% (118 of the 291 patients). Seventy-one patients (21%) had stage 1 AKI, 16 (6%) had stage 2 AKI, and 41 (14%) had stage 3 AKI. The development of severe sepsis or septic shock during follow-up was documented in 49% (58 of 118) (p<0.05). In the group that developed AKI, male sex predominated (75% vs. 64%) in the group without AKI, respectively), older age (61 vs. 54 years), and prolonged hospital stay (12 vs. 7.7 days) (p < 0.05). Approximately 50% of patients with AKI had some type of associated comorbidity (DM or SAH) compared to only 30% in the group without AKI (p < 0.05). The use of dexamethasone, angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARBs) was similar in both groups, whereas the use of diuretics was higher in patients with AKI. The highest points in severity on the APACHE II and SOFA scores at the time of hospital admission were recorded in patients who developed AKI (p<0.05). Baseline hemoglobin, platelets, leukocytes, lymphocytes, CRP, LDH, and ferritin levels at hospital admission did not differ between groups, while glucose levels (215 vs. 161), PCT (0.72 vs. 0.16), and D-dimer (670 mg/dL vs. 327 mg/dL) (p=0.001) were significantly higher in patients with AKI than in those without AKI. During follow-up, inflammatory markers in AKI stages 2 and 3 presented higher levels of PCT on days 6 and 12 (p = 0.009and p = 0.012, respectively), ferritin on days 6 and 12 (p=NS), and D-dimer on day 6 (p= 0.017). TABLE 2

	AKI total	AKI 1	AKI 2 and 3	
	N = 118	N = 61	N = 57	
Ferritin				
On hospitalization	884±592	839±479	933±699	
Day-3	815±508	637±392	964±520	
Day-6	846±499	594±423	1111±439	
Day-12	972±510	781±516	1104±482	
LDH (u/L)				
On hospitalization	428±166	396±168	462±158	
Day-3	474±391 [§]	388±249	578±498	
Day-6	383±157	368±132	416±176	
Day-12	339±140	340±153	339±133	
D-Dimer (ng/mL)				
On hospitalization	670 (230-2706)	543 (210-1830)	970 (274-3260)	
Day-3	1259 (472-4308)	921(239-3683)	2264 (855-2264)	
Day-6	1727 (646-3911)	960 (588-2534)*	2928 (868-5000)*	
Day-12	1782 (708-3201)	1007 (461-1940)	2234 (1702-4452)	
CRP (mg/dL)				
On hospitalization	158±110	148±109	171±112	
Day-3	105±100 [§]	83±86	125±107	
Day-6	85±91	78±110	91±72	
Day-12	115±76	81±76	143±66	
Procalcitonin (ng/mL)				
On hospitalization	0.72 (0.34-2.01)	0.53 (0.22-1.13)*	1.0 (0.52-2.80)*	
Day-3	0.42(0.20-1.90)	0.28 (0.15-0.64)*	1.13 (0.33-7.52)*	
Day-6	0.49 (0.16-1.56)	0.23 (0.1162)*	1.29 (0.20-3.9)*	
Day-12	1.18 (0.37-2.96)	0.43 (0.15-1.16)*	1.94 (0.56-6.10)*	

AKI: acute kidney injury; **CRP**: C-reactive protein; **LDH**: lactate dehydrogenase; p<0.05 vs. No AKI *p=<0.05 AKI 1 vs. AKI 2 and 3.

220 221

218

225

227

228

229

230

231

232


233

In the multivariate analysis, phosphate higher (p = 0.002, RR 1.39, CI 95% 1.13 – 1.72), PCT level >0.5 ng/ml on hospitalization (p = 0.005, RR 2.09, CI 95% 1.26-3.50), and points >15 (p224 = 0.011; RR 2.0 CI 95% 1.17-3.40) showed a significant association with the development of AKI. TABLE 3 226

Table 3. Multivariate analysis for risk factors associated with AKI in patients with COVID-19.

	Multivariate Analysis			
Variable	RR	CI 95%	Р	
Phosphate	1.39	1.13 – 1.72	0.002	
APACHE	2.0	1.17 – 3.40	0.011	
Procalcitonin	2.09	1.26 – 3.50	0.005	

Fifty-five percent of those who developed AKI recovered kidney function, the majority of whom had AKI stage 1. The survival analysis free of AKI according to PCT levels (≥ 0.5 ng/ml) (p = 0.001) and points on the APACHE score (>15 points) (p = 0.004) demonstrated a lower survival. FIGURE 1.



DISCUSSION

234

235

236

237

The present study concurs with the Latin American registry (30), which describes a high frequency of AKI (65%). In Mexico, incidences of 33.7 and 58.6% are reported, where half

238 correspond to severe cases, with comorbidities consistent with the present study, where we 239 documented that 30% of patients were overweight or had some degree of obesity.(31, 32) The development of AKI has been associated not only with obesity but also with being 240 241 overweight (33). The present study did not perform an analysis of the obesity subgroups, but both study groups had similar BMIs, and there was no demonstrated association with the 242 development of AKI. We found a high prevalence of SAH and DM with higher 243 244 concentrations of glucose and HbA1C in those who developed AKI, but these were not 245 associated with risk. Our results are consistent with the literature, where age is a risk factor 246 for severe illness (19) and leads to a higher risk of AKI (34). Hirsch et al. demonstrated a higher risk of AKI (OR 1.03, CI 95% 1.03-1.04; p < 0.001) in those aged >60 years (7). 247 248 Similarly, Fisher et al. (35) reported that older age (67 vs. 60 years; p < 0.001) was an independent risk factor for developing AKI. In Mexico, Casas-Aparicio et al. associated 249 250 higher age with AKI development (OR 1.07, CI 95% 1.01 - 1.13; p = 0.024) (31). In our cohort, although the AKI group were older (61 \pm 14 vs 54 \pm 13; p < 0.001), we were unable to 251 252 consolidate these results not achieving statistical significance. Hyperphosphatemia is related 253 to the risks of AKI and mortality(36). In this cohort we did not find hyperphosphatemia but but phosphathe levels were higher in AKI group. There is evidence that AKI is a phenomenon 254 255 associated with the activation of proinflammatory cytokines, and with this, it calls for the use 256 of markers of kidney injury (27). Some biomarkers predict AKI(37); however, the high costs and lack of availability of these tests in our region forced us to use biochemical parameters 257 258 that are within reach in our practice to predict AKI events. PCT is barely detectable in healthy 259 individuals; however, diverse conditions tend to elevate it (surgery, trauma, burns, 260 pancreatitis, and sepsis), where levels can be markedly high (38-42). One of the advantages of 261 PCT is its rapid increase 6 h after the onset of the inflammatory process (27). The elimination pathway of PCT is not clear, but due to its low molecular weight and deterioration of kidney 262 function, it can elevate its levels; therefore, it is not a reliable parameter in the case of illness 263 because the thresholds are different (43-45). Considering this aspect, the present study 264 excluded patients with the onset of deterioration of kidney function and any patient who had 265 conditions that would affect PCT values. The present multivariate analysis showed a 266 significant risk for the development of AKI, with PCT rates >0.5 ng/ml at the moment of 267 hospitalization. Some studies have demonstrated an association between PCT and the 268 development of kidney damage in contexts other than COVID-19 (20, 38-40). Feng et al. 269 270 showed the sensitivity (76%) and specificity (75%) of PCT in predicting AKI (OR 9.63, 95% 271 CI 95% 4.38–21.18) (38), and Chun K. et al. (39) reported that in septic patients hospitalized

273

274275

276

277278

279

280

281282

283284

285 286

287

288 289

290

291292

293

294295

296

297

298

299 300

301

302303

304 305 14

in an intensive care unit (ICU), PCT was significantly high (p < 0.001) and was associated with AKI (OR 1.006, 1,000–1,011; p=0.035). In the present study, 50% of the patients who developed AKI had a case of severe sepsis or septic shock that developed during their hospital stay (p < 0.05); however, our analysis did not demonstrate an association of the risk for the development of AKI. Regarding COVID-19, Wang et al. found that PCT levels were a predictor of kidney damage (46). This association can be measured by an exaggerated inflammatory response, even if the pathophysiological mechanism is unclear (47, 48). As a crucial component of the inflammatory cascade, the expression of PCT can be correlated with the levels of systemic inflammation and the development of AKI in patients with COVID-19 (63). Procalcitonin is a chemoattractant produced by monocytes in the inflammatory area, which contributes to the increase and recruitment of parenchymal cells with greater release of cytokines associated with acute kidney damage (39). Another implicated mechanism is the direct toxic effect of PCT on mesangial cells and apoptosis (48). Additionally, other markers demonstrate increments dependent on the reduction of the GFT (49), and in AKI, CRP and Ddimer levels have been shown to be high (31). The reduction in kidney function can explain our results of the increase in D-dimer levels predominantly in stages 2 and 3 of AKI; however, the analysis did not show an association with the risk for AKI. In severely ill patients, the APACHE II score is used over the long term to predict hospital mortality up to 28 days in different contexts (sepsis and pancreatitis). Zou et al. documented excellent discriminative power for mortality in patients with COVID-19 with point scores ≥ 17 (50). In the context of COVID-19, the APACHE II score was also associated with AKI in a Latin American cohort (OR 1.97, CI 95% 1.08-2.64; p<0.05), with higher mortality in those who had higher point scores (OR 1.08, CI 95%, 1.02-1.98; p<0.05) and in those who developed stage 3 AKI (OR 1.11, CI 95%, 1.05-2.57; p < 0.05). These data support that in COVID-19 patients, AKI is a decisive phenomenon in the prognosis of these patients (67). In different studies on patients with COVID-19, higher APACHE II scores have been associated with poor prognosis and AKI severity (68, 69). We found that >15 points on the APACHE II score demonstrated significance for the development of AKI, which could be explained by the severity of the clinical scenario of COVID-19 and the patient's comorbidities upon hospitalization. Until now, it remains unknown whether recovery from AKI in COVID-19 differs from other forms of AKI, and the direct, long-term impact of the SARS CoV-2 virus on kidney function in those who regain function remains unclear; however, the recommendation is a follow-up period of at least 2 to 3 months(51). Despite the high incidence of AKI, the majority of our patients had a favorable prognosis regarding recovery of

kidney function, since more than half of the patients studied had an improvement in GFR; 306 307 however, progression from stages 2 to 3 was associated with poor recovery. **CONCLUSIONS** 308 In this retrospective cohort, significantly high PCT levels were found on hospital admission in 309 310 patients who developed AKI, and this was a predictor of AKI development. The trajectory of PCT throughout the follow-up did not show significant differences between those who did 311 and did not develop AKI. Therefore, the use of PCT reinforces the importance of this marker 312 as a predictor for the development of AKI in patients with COVID-19 infection without 313 314 superinfections when admitted to the hospital. 315 **LIMITATIONS** The present study had some limitations. We recognize that this study is unicentric. However, 316 being a referral center for patients infected with SARS-CoV-2 who do not have social security 317 318 in our region favors extrapolation of the results to other populations, especially in those with limited access to health care. The majority of patients before hospitalization had passed a 319 320 considerable amount of time since acquiring the viral infection; therefore, subclinical bacterial superinfection could not be ruled out. Economic limitations (lack of treatment with 321 continuous slow therapies) could influence the lack of recovery of kidney function, especially 322 323 in those who developed severe AKI. Finally, the lack of measurement and/or comparison of 324 markers valid for AKI does not permit the determination of PCT levels. 325 **Data Availability** Most clinical data are restricted to protecting information from misuse. The data may be 326 shared by the OPD, Hospital Civil de Guadalajara, and Dr. Juan I Menchaca (HCG-JIM) after 327 328 approval from the Ethics Committee of the Institution. The data supporting the findings of this study are available from the corresponding author upon reasonable request. 329 **Conflict of interest** 330

All the authors have declared no conflicts of interest.

Funding statement

331

332

The study did not receive any private or governmental funding.

Acknowledgements

Not applicable.

334

336

344

345346347348

349

Author Contributions

- a) Conception and design for: Jorge Andrade-Sierra, Claudia Delgado Astorga and
 Enrique Rojas Campos.
- b) Analysis and interpretation of data: Jorge Andrade-Sierra, Claudia Delgado Astorga,
 Miriam Gabriela Nava Vargas and Enrique Rojas Campos.
- c) Drafting and critically revising the article for important intellectual content: Jorge Andrade-Sierra, Karla Hernández Morales, Carlos A Andrade Castellanos, Javier Arellano Arteaga, Andrade-Ortega Antonio de Jesús, Luis Gerardo González-Correa.
 - d) Final approval of the version to be published: All the team.

REFERENCES

- 350 1. https://covid19.who.int/region/amro/country/mx.
- 2. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of
- mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.
- 353 J Med Virol. 2020;92(10):1875-83.
- 354 3. Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, et al.
- 355 COVID-19 mortality risk assessment: An international multi-center study. PLoS One.
- 356 2020;15(12):e0243262.
- 4. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is
- associated with in-hospital death of patients with COVID-19. Kidney Int.
- 359 2020;97(5):829-38.
- 5. Izzedine H, Jhaveri KD. Acute kidney injury in patients with COVID-19: an update
- on the pathophysiology. Nephrol Dial Transplant. 2021;36(2):224-6.
- 6. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and
- Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol.
- 364 2020;31(6):1157-65.
- 7. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute
- kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18.
- 8. Moledina DG, Simonov M, Yamamoto Y, Alausa J, Arora T, Biswas A, et al. The
- Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness:
- A Multicenter Cohort Study. Am J Kidney Dis. 2021;77(4):490-9 e1.
- 9. Singh J, Malik P, Patel N, Pothuru S, Israni A, Chakinala RC, et al. Kidney
- disease and COVID-19 disease severity-systematic review and meta-analysis. Clin
- 372 Exp Med. 2022:22(1):125-35.
- 10. Raina R, Mahajan ZA, Vasistha P, Chakraborty R, Mukunda K, Tibrewal A, et al.
- Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review.
- 375 Blood Purif. 2022;51(3):199-212.

- 11. Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al. Survival
- rate in acute kidney injury superimposed COVID-19 patients: a systematic review and
- meta-analysis. Ren Fail. 2020;42(1):393-7.
- 12. Lim JH, Park SH, Jeon Y, Cho JH, Jung HY, Choi JY, et al. Fatal Outcomes of
- 380 COVID-19 in Patients with Severe Acute Kidney Injury. J Clin Med. 2020;9(6).
- 13. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a
- target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat
- 383 Commun. 2021;12(1):2506.
- 14. Abbate M, Rottoli D, Gianatti A. COVID-19 Attacks the Kidney: Ultrastructural
- Evidence for the Presence of Virus in the Glomerular Epithelium. Nephron.
- 386 2020;144(7):341-2.
- 15. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-
- 388 CoV-2? Am J Physiol Renal Physiol. 2020;318(6):F1454-F62.
- 16. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for
- extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308-10.
- 17. Nadim MK, Forni LG, Mehta RL, Connor MJ, Jr., Liu KD, Ostermann M, et al.
- 392 COVID-19-associated acute kidney injury: consensus report of the 25th Acute
- Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747-64.
- 18. Joannidis M, Forni LG, Klein SJ, Honore PM, Kashani K, Ostermann M, et al.
- Lung-kidney interactions in critically ill patients: consensus report of the Acute
- Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med. 2020;46(4):654-72.
- 19. Ou M, Zhu J, Ji P, Li H, Zhong Z, Li B, et al. Risk factors of severe cases with
- 399 COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:e175.
- 20. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein,
- procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-
- analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
- 403 21. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in
- diagnosis of COVID-19 A systematic review. Life Sci. 2020;254:117788.
- 405 22. Ciaccio M, Agnello L. Biochemical biomarkers alterations in Coronavirus Disease
- 406 2019 (COVID-19). Diagnosis (Berl). 2020;7(4):365-72.
- 23. Menez S, Moledina DG, Thiessen-Philbrook H, Wilson FP, Obeid W, Simonov M,
- 408 et al. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With
- 409 COVID-19. Am J Kidney Dis. 2022;79(2):257-67 e1.
- 410 24. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19
- cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151.
- 25. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19
- 413 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446.
- 26. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients
- with COVID-19. Lancet Respir Med. 2020;8(7):738-42.
- 27. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al.
- A new equation to estimate glomerular filtration rate. Ann Intern Med.
- 418 2009;150(9):604-12.
- 419 28. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
- 29. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR,
- et al. Nomenclature for kidney function and disease: report of a Kidney Disease:
- 422 Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int.
- 423 2020;97(6):1117-29.
- 424 30. Lombardi R, Ferreiro A, Ponce D, Claure-Del Granado R, Aroca G, Venegas Y,
- et al. Latin American registry of renal involvement in COVID-19 disease. The

- relevance of assessing proteinuria throughout the clinical course. PLoS One.
- 427 2022;17(1):e0261764.
- 31. Casas-Aparicio GA, Leon-Rodriguez I, Alvarado-de la Barrera C, Gonzalez-
- Navarro M, Peralta-Prado AB, Luna-Villalobos Y, et al. Acute kidney injury in patients
- with severe COVID-19 in Mexico. PLoS One. 2021;16(2):e0246595.
- 32. Chavez-Iniguez JS, Cano-Cervantes JH, Maggiani-Aguilera P, Lavelle-Gongora
- N, Marcial-Meza J, Camacho-Murillo EP, et al. Mortality and evolution between
- community and hospital-acquired COVID-AKI. PLoS One. 2021;16(11):e0257619.
- 33. van Son J, Oussaada SM, Sekercan A, Beudel M, Dongelmans DA, van Assen
- S, et al. Overweight and Obesity Are Associated With Acute Kidney Injury and Acute
- Respiratory Distress Syndrome, but Not With Increased Mortality in Hospitalized
- 437 COVID-19 Patients: A Retrospective Cohort Study. Front Endocrinol (Lausanne).
- 438 2021;12:747732.
- 34. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in
- Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151-60.
- 35. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in
- Hospitalized Patients with and without COVID-19: A Comparison Study. J Am Soc
- 443 Nephrol. 2020;31(9):2145-57.
- 36. Moon H, Chin HJ, Na KY, Joo KW, Kim YS, Kim S, et al. Hyperphosphatemia
- and risks of acute kidney injury, end-stage renal disease, and mortality in hospitalized
- patients. BMC Nephrol. 2019;20(1):362.
- 37. Lin J, Chen J, Wu D, Li X, Guo X, Shi S, et al. Biomarkers for the early prediction
- of contrast-induced nephropathy after percutaneous coronary intervention in adults:
- A systematic review and meta-analysis. Angiology. 2022;73(3):207-17.
- 38. Feng Y, He H, Jia C, Xu Z, Li Y, Liao D. Meta-analysis of procalcitonin as a
- predictor for acute kidney injury. Medicine (Baltimore). 2021;100(10):e24999.
- 39. Chun K, Chung W, Kim AJ, Kim H, Ro H, Chang JH, et al. Association between
- acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in
- 454 critically ill patients. Sci Rep. 2019;9(1):4777.
- 455 40. Nie X, Wu B, He Y, Huang X, Dai Z, Miao Q, et al. Serum procalcitonin predicts
- development of acute kidney injury in patients with suspected infection. Clin Chem
- 457 Lab Med. 2013;51(8):1655-61.
- 41. Dias BH, Rozario AP, Olakkengil SA, V A. Procalcitonin Strip Test as an
- 459 Independent Predictor in Acute Pancreatitis. The Indian journal of surgery.
- 460 2015;77(Suppl 3):1012-7.
- 42. Simsek O, Kocael A, Kocael P, Orhan A, Cengiz M, Balcı H, et al. Inflammatory
- mediators in the diagnosis and treatment of acute pancreatitis: pentraxin-3,
- procalcitonin and myeloperoxidase. Archives of Medical Science. 2018;14(2):288-96.
- 43. Level C, Chauveau P, Delmas Y, Lasseur C, Pelle G, Peuchant E, et al.
- Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial
- 466 Transplant. 2001;16(5):980-6.
- 44. Nakamura Y, Murai A, Mizunuma M, Ohta D, Kawano Y, Matsumoto N, et al.
- 468 Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or
- without acute kidney injury. J Infect Chemother. 2015;21(4):257-63.
- 45. Amour J, Birenbaum A, Langeron O, Le Manach Y, Bertrand M, Coriat P, et al.
- Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of
- postoperative infection after vascular surgery. Crit Care Med. 2008;36(4):1147-54.
- 473 46. Wang RR, He M, Kang Y. A risk score based on procalcitonin for predicting acute
- kidney injury in COVID-19 patients. J Clin Lab Anal. 2021;35(6):e23805.

- 476 2002;90(2):133-8.
- 48. Araujo M, Doi SQ, Palant CE, Nylen ES, Becker KL. Procalcitonin induced
- cytotoxicity and apoptosis in mesangial cells: implications for septic renal injury.
- 479 Inflamm Res. 2013;62(10):887-94.
- 49. Spring JL, Winkler A, Levy JH. The influence of various patient characteristics on
- D-dimer concentration in critically ill patients and its role as a prognostic indicator in
- the intensive care unit setting. Clin Lab Med. 2014;34(3):675-86.
- 50. Zou X, Li S, Fang M, Hu M, Bian Y, Ling J, et al. Acute Physiology and Chronic
- Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of
- 485 Coronavirus Disease 2019. Crit Care Med. 2020;48(8):e657-e65.
- 51. Kashani K, Rosner MH, Haase M, Lewington AJP, O'Donoghue DJ, Wilson FP,
- et al. Quality Improvement Goals for Acute Kidney Injury. Clin J Am Soc Nephrol.
- 488 2019;14(6):941-53.

489

490

- 492 Figure Legends
- 493 **Table 1.** Demographic characteristics of patients diagnosed with acute kidney injury (AKI)
- 494 and COVID-19.
- 495 **Table 2.** Markers of inflammation on hospitalization and during follow-up in patients with
- 496 COVID-19 and acute kidney injury (AKI).
- **Table 3.** Multivariate analysis for risk factors associated with acute kidney injury (AKI) in
- 498 patients with COVID-19.
- 499 **Figure 1.** Acute kidney injury-free time according to procalcitonin and APACHE score.